Abstract
We present the case of a patient with oral squamous cell carcinoma treated with the programmed death ligand inhibitor, pembrolizumab, an immune checkpoint inhibitor. She subsequently developed vasovagal-type autonomic dysfunction thought to be secondary to the pembrolizumab. The patient’s vasovagal symptoms resolved with the initiation of oral glucocorticoids.
Reference11 articles.
1. Keytruda . Package insert. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, 2017. Available: https://www.accessdata.fda. gov/drugsatfda_docs/label/2017/125514s014lbl. pdf [Accessed 06 Jan 2022].
2. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors;Choi;Immune Netw,2020
3. Immune-Related adverse events associated with immune checkpoint blockade;Postow;N Engl J Med Overseas Ed,2018
4. Shalata W , Yakobson A , Massalha I , et al . Unusual Adverse Effects of Immune Checkpoint Inhibitors: Autonomic Neuropathy, Palmoplantar Keratoderma, Reiter Syndrome & Myasthenia Gravis: A Case Series and Review of the Literature. Ijirms;5:554–60.doi:10.23958/ijirms/vol05-i11/982
5. Andrews S , Ludlow SP . Autonomic enteric neuropathy following nivolumab monotherapy in a patient with lung cancer. Curr Probl Cancer 2020;1:100014.doi:10.1016/j.cpccr.2020.100014